Results

RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/31355940http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/31355940http://www.w3.org/2000/01/rdf-schema#comment"

Aims

Patients with aggressive CD8+ cutaneous T-cell lymphomas (CTCLs) progress rapidly and respond poorly to therapy. Confounding treatment planning, there is clinicopathological overlap between aggressive CD8+ CTCLs and other lymphoproliferative disorders (LPDs). Hence, improved diagnostic methods and therapeutic options are needed. The aim of this study was to examine C-C chemokine receptor 4 (CCR4) expression as a diagnostic and therapeutic biomarker in CD8+ CTCLs/LPDs.

Methods and results

Forty-nine cases (41 patients) with CD8+ CTCLs/LPDs were examined, including CD8+ mycosis fungoides (MF) (n = 14), aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma (AETCL) (n = 8), subcutaneous panniculitis-like T-cell lymphoma (SPTCL) (n = 7), CD30+ LPDs (n = 6), primary cutaneous γδ T-cell lymphoma (GDTCL) (n = 6), and others (n = 8). Immunohistochemical tissue staining was performed with a CCR4 monoclonal antibody on formalin-fixed paraffin-embedded tissue sections. CCR4 immunostaining was graded as percentage infiltrate, i.e. high (>25%) and low (≤25%), and the results were correlated with clinicopathological diagnoses. CCR4 expression was seen in 69% of the studied cases. Any CCR4 positivity was seen in all CD8+ MF cases, in 83% of CD30+ LPD cases, in 75% of AETCL cases, in 33% of GDTCL cases, and in none of the SPTCL cases. High CCR4 expression was seen in 79% of CD8+ MF cases versus 33% of CD30+ LPD cases, in 17% of GDTCL cases, and in 12.5% of AETCL cases. Patients with more advanced MF stage had higher CCR4 expression.

Conclusions

CCR4 immunohistochemistry may be an adjunct in distinguishing advanced CD8+ MF from other CD8+ CTCLs/LPDs. Although CCR4 expression may justify therapeutic targeting of this receptor in CD8+ MF, the role of such therapies in other CD8+ CTCLs/LPDs is not yet clear."xsd:string
http://purl.uniprot.org/citations/31355940http://purl.org/dc/terms/identifier"doi:10.1111/his.13960"xsd:string
http://purl.uniprot.org/citations/31355940http://purl.uniprot.org/core/author"Hollmann T.J."xsd:string
http://purl.uniprot.org/citations/31355940http://purl.uniprot.org/core/author"Geller S."xsd:string
http://purl.uniprot.org/citations/31355940http://purl.uniprot.org/core/author"Pulitzer M."xsd:string
http://purl.uniprot.org/citations/31355940http://purl.uniprot.org/core/author"Horwitz S.M."xsd:string
http://purl.uniprot.org/citations/31355940http://purl.uniprot.org/core/author"Myskowski P.L."xsd:string
http://purl.uniprot.org/citations/31355940http://purl.uniprot.org/core/date"2020"xsd:gYear
http://purl.uniprot.org/citations/31355940http://purl.uniprot.org/core/name"Histopathology"xsd:string
http://purl.uniprot.org/citations/31355940http://purl.uniprot.org/core/pages"222-232"xsd:string
http://purl.uniprot.org/citations/31355940http://purl.uniprot.org/core/title"C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment."xsd:string
http://purl.uniprot.org/citations/31355940http://purl.uniprot.org/core/volume"76"xsd:string
http://purl.uniprot.org/citations/31355940http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/31355940
http://purl.uniprot.org/citations/31355940http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/31355940
http://purl.uniprot.org/uniprot/#_A0N0Q1-mappedCitation-31355940http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/31355940
http://purl.uniprot.org/uniprot/#_P51679-mappedCitation-31355940http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/31355940
http://purl.uniprot.org/uniprot/A0N0Q1http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/31355940
http://purl.uniprot.org/uniprot/P51679http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/31355940